Abstract

The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with severe infection from coronavirus disease 2019 (COVID-19) has been the subject of considerable debate. ACEIs and ARBs act on the renin-angiotensin-aldosterone system (RAAS) by attenuating the hypertensive effects of angiotensin II (Fig. 1) [1,2,3,4]. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.

Details

Title
ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking
Author
Onweni, Chidinma L; Zhang, Yu Shrike; Caulfield, Thomas; Hopkins, Christopher E; De Lisa Fairweather; Freeman, William D  VIAFID ORCID Logo 
Pages
1-3
Section
Research Letter
Publication year
2020
Publication date
2020
Publisher
BioMed Central
ISSN
13648535
e-ISSN
1366609X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s13054-020-03195-9
ProQuest document ID
2435081912
Copyright
© 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.